CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Salarius Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Salarius Pharmaceuticals Inc
2450 Holcombe Blvd Ste J-608
Phone: (617) 874-1821p:617 874-1821 HOUSTON, TX  77021-2041  United States Ticker: SLRXSLRX
Business Summary
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board William K.McVicar 65 6/19/2020 4/5/2017
President, Chief Executive Officer, Director David J.Arthur 60 7/19/2019 7/19/2019
Chief Financial Officer, Executive Vice President - Finance Mark J.Rosenblum 69 9/13/2019 9/13/2019
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Flex Innovation Group LLC 800 Boylston Street Boston MA United States

Business Names
Business Name
Flex Innovation Group LLC
FLKS
Salarius Pharmaceuticals, LLC
SLRX
TK Pharma, Inc.

General Information
Number of Employees: 2 (As of 3/8/2024)
Outstanding Shares: 4,776,433 (As of 4/16/2024)
Shareholders: 149
Stock Exchange: NASD
Federal Tax Id: 465087339
Fax Number: (302) 655-5049
Email Address: info@flex-pharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024